Claudio Tiribelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/764133/publications.pdf

Version: 2024-02-01

304 papers	21,995 citations	18482 62 h-index	11052 137 g-index
314 all docs	314 docs citations	314 times ranked	21639 citing authors

#	Article	IF	Citations
1	Glycosylated 4â€methylumbelliferone as a targeted therapy for hepatocellular carcinoma. Liver International, 2022, 42, 444-457.	3.9	3
2	MicroRNAs Related to TACE Treatment Response: A Review of the Literature from a Radiological Point of View. Diagnostics, 2022, 12, 374.	2.6	9
3	The Beneficial Effects of Triterpenic Acid and Acteoside in an In Vitro Model of Nonalcoholic Steatohepatitis (NASH). International Journal of Molecular Sciences, 2022, 23, 3562.	4.1	8
4	Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates. International Journal of Molecular Sciences, 2022, 23, 2764.	4.1	22
5	Ficolin-2 Plasma Level Assesses Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2022, 23, 2813.	4.1	2
6	Translational Approach to the Protective Effect of Bilirubin in Diabetic Kidney Disease. Biomedicines, 2022, 10, 696.	3.2	8
7	The Expression Level of ABCC6 Transporter in Colon Cancer Cells Correlates with the Activation of Different Intracellular Signaling Pathways. Pathophysiology, 2022, 29, 173-186.	2.2	1
8	Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals. Cancers, 2022, 14, 2700.	3.7	3
9	Role of hepatitis B virus in development of hepatocellular carcinoma: Focus on covalently closed circular DNA. World Journal of Hepatology, 2022, 14, 866-884.	2.0	4
10	Vascular network expansion, integrity of bloodâ€“brain interfaces, and cerebrospinal fluid cytokine concentration during postnatal development in the normal and jaundiced rat. Fluids and Barriers of the CNS, 2022, 19, .	5.0	8
11	Nonalcoholic Fatty Liver Disease and Altered Neuropsychological Functions in Patients with Subcortical Vascular Dementia. Journal of Personalized Medicine, 2022, 12, 1106.	2.5	6
12	Modifications of IGF2 and EGFR plasma protein concentrations in NAFLD patients after bariatric surgery. International Journal of Obesity, 2021, 45, 374-382.	3.4	1
13	Circulating Long and Circular Noncoding RNA as Non-Invasive Diagnostic Tools of Hepatocellular Carcinoma. Biomedicines, 2021, 9, 90.	3.2	27
14	Homocysteine in Neurology: A Possible Contributing Factor to Small Vessel Disease. International Journal of Molecular Sciences, 2021, 22, 2051.	4.1	27
15	External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study. Journal of Clinical Medicine, 2021, 10, 520.	2.4	15
16	Life-Long Hyperbilirubinemia Exposure and Bilirubin Priming Prevent In Vitro Metabolic Damage. Frontiers in Pharmacology, 2021, 12, 646953.	3.5	5
17	The Role of microRNAs in the Cisplatin- and Radio-Resistance of Cervical Cancer. Cancers, 2021, 13, 1168.	3.7	25
18	Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive toolsâ€”a narrative review. Annals of Translational Medicine, 2021, 9, 727-727.	1.7	3

#	Article	IF	Citations
19	Screening methods for neonatal hyperbilirubinemia: benefits, limitations, requirements, and novel developments. Pediatric Research, 2021, 90, 272-276.	2.3	18
20	Diagnostic methods for neonatal hyperbilirubinemia: benefits, limitations, requirements, and novel developments. Pediatric Research, 2021, 90, 277-283.	2.3	22
21	HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development. Cancers, 2021, 13, 2485.	3.7	12
22	Bilirubin: The yellow hormone?. Journal of Hepatology, 2021, 75, 1485-1490.	3.7	47
23	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. Gastroenterology, 2021, 160, 2483-2495.e26.	1.3	27
24	Association of Serum Bilirubin Level with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study of 1672 Obese Children. Journal of Clinical Medicine, 2021, 10, 2812.	2.4	9
25	Bilirubin: A Promising Therapy for Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 6223.	4.1	7
26	COVID-19 Lockdown Effect on Not Institutionalized Patients with Dementia and Caregivers. Healthcare (Switzerland), 2021, 9, 893.	2.0	13
27	Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World Journal of Stem Cells, 2021, 13, 795-824.	2.8	7
28	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. Journal of Hepatology, 2021, 75, 572-581.	3.7	62
29	The Multifaceted Aspects of Modern Hepatology. Annals of Hepatology, 2021, , 100536.	1.5	0
30	Taste perception and expression in stomach of bitter taste receptor tas2r38 in obese and lean subjects. Appetite, 2021, 166, 105595.	3.7	7
31	The Relevance of SOCS1 Methylation and Epigenetic Therapy in Diverse Cell Populations of Hepatocellular Carcinoma. Diagnostics, 2021, 11, 1825.	2.6	4
32	Curcumin Prevents Cerebellar Hypoplasia and Restores the Behavior in Hyperbilirubinemic Gunn Rat by a Pleiotropic Effect on the Molecular Effectors of Brain Damage. International Journal of Molecular Sciences, 2021, 22, 299.	4.1	8
33	Hepatitis C Virus-Related Central and Peripheral Nervous System Disorders. Brain Sciences, 2021, 11, 1569.	2.3	5
34	Spleen Stiffness Probability Index (SSPI): A simple and accurate method to detect esophageal varices in patients with compensated liver cirrhosis. Annals of Hepatology, 2020, 19, 53-61.	1.5	31
35	Circulatory miRNA as a Biomarker for Therapy Response and Disease-Free Survival in Hepatocellular Carcinoma. Cancers, 2020, 12, 2810.	3.7	21
36	The Role of Bilirubin and the Other â€œYellow Playersâ€•in Neurodegenerative Diseases. Antioxidants, 2020, 9, 900.	5.1	15

#	Article	IF	Citations
37	Optimization of Point-Shear Wave Elastography by Skin-to-Liver Distance to Assess Liver Fibrosis in Patients Undergoing Bariatric Surgery. Diagnostics, 2020, 10, 795.	2.6	15
38	HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance. Hepatic Oncology, 2020, 7, HEP21.	4.2	6
39	Bilirubin, Intestinal Integrity, the Microbiome, and Inflammation. New England Journal of Medicine, 2020, 383, 684-686.	27.0	31
40	Differential capacity of CD90+ cells in autophagy activation following chemotherapy in hepatocellular carcinoma. Annals of Hepatology, 2020, 19, 645-652.	1.5	4
41	Spleen stiffness can be employed to assess the efficacy of spontaneous portosystemic shunts in relieving portal hypertension. Annals of Hepatology, 2020, 19, 691-693.	1.5	10
42	The mRNA Distribution of Cancer Stem Cell Marker CD90/Thy-1 Is Comparable in Hepatocellular Carcinoma of Eastern and Western Populations. Cells, 2020, 9, 2672.	4.1	4
43	Weighted miRNA co-expression networks analysis identifies circulating miRNA predicting overall survival in hepatocellular carcinoma patients. Scientific Reports, 2020, 10, 18967.	3.3	17
44	The Extent of Intracellular Accumulation of Bilirubin Determines Its Anti- or Pro-Oxidant Effect. International Journal of Molecular Sciences, 2020, 21, 8101.	4.1	19
45	Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity. Cancers, 2020, 12, 1576.	3.7	90
46	Differentiation between stages of non-alcoholic fatty liver diseases using surface-enhanced Raman spectroscopy. Analytica Chimica Acta, 2020, 1110, 190-198.	5.4	25
47	Selection and validation of miR-1280 as a suitable endogenous normalizer for qRT-PCR Analysis of serum microRNA expression in Hepatocellular Carcinoma. Scientific Reports, 2020, 10, 3128.	3.3	9
48	Bilirubin disrupts calcium homeostasis in neonatal hippocampal neurons: a new pathway of neurotoxicity. Archives of Toxicology, 2020, 94, 845-855.	4.2	18
49	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158, 1999-2014.e1.	1.3	1,840
50	Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. Scientific Reports, 2020, 10, 1699.	3.3	26
51	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 2020, 73, 202-209.	3.7	2,171
52	Circulating microRNA Associated to Different Stages of Liver Steatosis in Praderâ€“Willi Syndrome and Non-Syndromic Obesity. Journal of Clinical Medicine, 2020, 9, 1123.	2.4	4
53	Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population Study. Journal of Clinical Medicine, 2020, 9, 1177.	2.4	15
54	Occult hepatitis B virus infection predicts nonâ€alcoholic steatohepatitis in severely obese individuals from Italy. Liver International, 2020, 40, 1601-1609.	3.9	11

#	Article	IF	Citations
55	The Crosstalk between Tumor Cells and the Microenvironment in Hepatocellular Carcinoma: The Role of Exosomal microRNAs and Their Clinical Implications. Cancers, 2020, 12, 823.	3.7	40
56	Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population?. Annals of Hepatology, 2020, 19, 380-387.	1.5	19
57	Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease. , 2020, 1, 51-74.		18
58	Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals. Cancers, 2019, 11, 1773.	3.7	31
59	The Novel N,Nâ€bisâ€2â€Hydroxyethylâ€2â€Aminoethanesulfonic Acidâ€“Gluconateâ€“Polyethylene Glycolâ€“Hypothermic Machine Perfusion Solution Improves Static Cold Storage and Reduces Ischemia/Reperfusion Injury in Rat Liver Transplant. Liver Transplantation, 2019, 25, 1375-1386.	2.4	5
60	Why, What and Where: 3W in hepatology. Annals of Hepatology, 2019, 18, 409.	1.5	2
61	A comparative characterization of the circulating miRNome in whole blood and serum of HCC patients. Scientific Reports, 2019, 9, 8265.	3.3	31
62	Earliest Mechanisms of Dopaminergic Neurons Sufferance in a Novel Slow Progressing Ex Vivo Model of Parkinson Disease in Rat Organotypic Cultures of Substantia Nigra. International Journal of Molecular Sciences, 2019, 20, 2224.	4.1	15
63	Silybin Modulates Collagen Turnover in an In Vitro Model of NASH. Molecules, 2019, 24, 1280.	3.8	8
64	Hyaluronic acid inhibition by 4-methylumbelliferone reduces the expression of cancer stem cells markers during hepatocarcinogenesis. Scientific Reports, 2019, 9, 4026.	3.3	25
65	Blue or green for yellow? Which light is more beneficial for jaundiced newborns?. Pediatric Research, 2019, 85, 747-747.	2.3	3
66	Serum AP-endonuclease 1 (sAPE1) as novel biomarker for hepatocellular carcinoma. Oncotarget, 2019, 10, 383-394.	1.8	33
67	Induction of Mild Hyperbilirubinemia: Hype or Real Therapeutic Opportunity?. Clinical Pharmacology and Therapeutics, 2019, 106, 568-575.	4.7	53
68	The role of microRNA in the resistance to treatment of hepatocellular carcinoma. Annals of Translational Medicine, 2019, 7, 577-577.	1.7	38
69	Attenuation of neuro-inflammation improves survival and neurodegeneration in a mouse model of severe neonatal hyperbilirubinemia. Brain, Behavior, and Immunity, 2018, 70, 166-178.	4.1	39
70	Global epidemiology of nonâ€alcoholic fatty liver disease/nonâ€alcoholic steatohepatitis: What we need in the future. Liver International, 2018, 38, 47-51.	3.9	297
71	Two drinks per day does not take your fatty liver away. Hepatology, 2018, 67, 2072-2073.	7.3	2
72	A simple in silico strategy identifies candidate biomarkers for the diagnosis of liver fibrosis in morbidly obese subjects. Liver International, 2018, 38, 155-163.	3.9	5

#	Article	IF	Citations
73	A New Stage in Annals of Hepatology. Annals of Hepatology, 2018, 17, 339-340.	1.5	4
74	Bilirubin-Induced Oxidative Stress Leads to DNA Damage in the Cerebellum of Hyperbilirubinemic Neonatal Mice and Activates DNA Double-Strand Break Repair Pathways in Human Cells. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-11.	4.0	41
75	Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study. BMC Gastroenterology, 2018, 18, 177.	2.0	23
76	Activation of hepatic stem cells compartment during hepatocarcinogenesis in a HBsAg HBV-transgenic mouse model. Scientific Reports, 2018, 8, 13168.	3.3	11
77	Histone acetylation as a new mechanism for bilirubin-induced encephalopathy in the Gunn rat. Scientific Reports, 2018, 8, 13690.	3.3	17
78	Diagnostic Performance Analysis of the Point-of-Care Bilistick System in Identifying Severe Neonatal Hyperbilirubinemia by a Multi-Country Approach. EClinicalMedicine, 2018, 1, 14-20.	7.1	20
79	Differences in circulating microRNA signature in Praderâ€“Willi syndrome and non-syndromic obesity. Endocrine Connections, 2018, 7, 1262-1274.	1.9	10
80	Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research. World Journal of Hepatology, 2018, 10, 231-245.	2.0	18
81	Kernicterus, Bilirubin-Induced Neurological Dysfunction, and New Treatments for Unconjugated Hyperbilirubinemia in Neonates. , 2018, , 1169-1184.		0
82	Evaluation of region selective bilirubin-induced brain damage as a basis for a pharmacological treatment. Scientific Reports, 2017, 7, 41032.	3.3	23
83	UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population. Liver International, 2017, 37, 1345-1353.	3.9	18
84	The molecular basis of jaundice: An old symptom revisited. Liver International, 2017, 37, 1094-1102.	3.9	25
85	The activation of autophagy protects neurons and astrocytes against bilirubin-induced cytotoxicity. Neuroscience Letters, 2017, 661, 96-103.	2.1	23
86	New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma. Journal of Controlled Release, 2017, 268, 184-197.	9.9	33
87	Editorial: treatments for nonâ€alcoholic steatohepatitis â€•still a long way to go. Alimentary Pharmacology and Therapeutics, 2017, 46, 700-701.	3.7	0
88	Is it time to change NAFLD and NASH nomenclature?. The Lancet Gastroenterology and Hepatology, 2017, 2, 547-548.	8.1	32
89	Hepatocyte-derived macrophage migration inhibitory factor mediates alcohol-induced liver injury in mice and patients. Journal of Hepatology, 2017, 67, 1018-1025.	3.7	48
90	Bilirubin-induced ER stress contributes to the inflammatory response and apoptosis in neuronal cells. Archives of Toxicology, 2017, 91, 1847-1858.	4.2	29

#	Article	IF	Citations
91	Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis. Nutrients, 2017, 9, 1006.	4.1	28
92	Vitamin D, Homocysteine, and Folate in Subcortical Vascular Dementia and Alzheimer Dementia. Frontiers in Aging Neuroscience, 2017, 9, 169.	3.4	48
93	Homocysteine in Neurology: From Endothelium to Neurodegeneration. Current Nutrition and Food Science, 2017, 13, .	0.6	11
94	Genetic biomarkers for hepatocellular cancer risk in a caucasian population. World Journal of Gastroenterology, 2017, 23, 6674-6684.	3.3	26
95	Role of brain cytochrome P450 mono-oxygenases in bilirubin oxidation-specific induction and activity. Archives of Toxicology, 2016, 90, 279-290.	4.2	17
96	Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis. World Journal of Gastroenterology, 2016, 22, 9096.	3.3	39
97	A Hypothesis for Using Pathway Genetic Load Analysis for Understanding Complex Outcomes in Bilirubin Encephalopathy. Frontiers in Neuroscience, 2016, 10, 376.	2.8	14
98	Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology, 2016, 63, 827-838.	7.3	467
99	Natural history of nonalcoholic steatohepatitisâ€“associated hepatocellular carcinoma. Clinical Liver Disease, 2016, 8, 105-107.	2.1	2
100	Modulation of bilirubin neurotoxicity by the Abcb1 transporter in theUgt1-/-lethal mouse model of neonatal hyperbilirubinemia. Human Molecular Genetics, 2016, 26, ddw375.	2.9	13
101	Neonatal Jaundice in Low- and Middle-Income Countries: Lessons and Future Directions from the 2015 Don Ostrow Trieste Yellow Retreat. Neonatology, 2016, 110, 172-180.	2.0	108
102	A Novel Perspective on the Biology of Bilirubin in Health and Disease. Trends in Molecular Medicine, 2016, 22, 758-768.	6.7	147
103	Nonalcoholic Fatty Liver Is Not Associated with the Relationship between Insulin Secretion and Insulin Sensitivity in Obese Children: Matched Caseâ€“Control Study. Childhood Obesity, 2016, 12, 426-431.	1.5	4
104	Cryopreservation by slow cooling of rat neuronal cells. Cryobiology, 2016, 72, 191-197.	0.7	10
105	The Biological Effects of Bilirubin Photoisomers. PLoS ONE, 2016, 11, e0148126.	2.5	27
106	An Animal Model for the Juvenile Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. PLoS ONE, 2016, 11, e0158817.	2.5	45
107	Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 1497.	3.3	47
108	ÂRapid identification system of frontal dysfunction in subclinical hepatic encephalopathy. Annals of Hepatology, 2016, 15, 559-67.	1.5	3

#	Article	IF	Citations
109	Transcriptional Up-Regulation of APE1/Ref-1 in Hepatic Tumor: Role in Hepatocytes Resistance to Oxidative Stress and Apoptosis. PLoS ONE, 2015, 10, e0143289.	2.5	30
110	The importance of the interaction between hepatocyte and hepatic stellate cells in fibrogenesis induced by fatty accumulation. Experimental and Molecular Pathology, 2015, 98, 85-92.	2.1	42
111	The effect of a hydrogen sulfide releasing molecule (Na2S) on the cold storage of livers from cardiac dead donor rats. A study in an ex vivo model. Cryobiology, 2015, 71, 24-32.	0.7	12
112	Multidrug resistance in hepatic cancer stem cells: the emerging role of miRNAs. Expert Review of Gastroenterology and Hepatology, 2015, 9, 723-725.	3.0	5
113	The interplay between hepatic stellate cells and hepatocytes in an in vitro model of NASH. Toxicology in Vitro, 2015, 29, 1753-1758.	2.4	49
114	Silencing efficacy prediction: a retrospective study on target mRNA features. Bioscience Reports, 2015, 35, .	2.4	13
115	Looking to the horizon: the role of bilirubin in the development and prevention of age-related chronic diseases. Clinical Science, 2015, 129, 1-25.	4.3	126
116	The role of multipotent cancer associated fibroblasts in hepatocarcinogenesis. BMC Cancer, 2015, 15, 188.	2.6	55
117	The multiple origin of cancer stem cells in hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, S92-S97.	1.5	16
118	The Pros and the Cons for the Use of Silybin-Rich Oral Formulations in Treatment of Liver Damage (NAFLD in Particular). Current Medicinal Chemistry, 2015, 22, 2954-2971.	2.4	9
119	Kinetics of the inflammatory response induced by free fatty acid accumulation in hepatocytes. Annals of Hepatology, 2014, 13, 113-120.	1.5	16
120	Bilirubin-Induced Neurologic Damage. New England Journal of Medicine, 2014, 370, 978-979.	27.0	14
121	Recent insights into hepatic cancer stem cells. Hepatology International, 2014, 8, 458-463.	4.2	2
122	The impact of translational research on gastroenterology. Digestive and Liver Disease, 2014, 46, 293-294.	0.9	1
123	Cross-Talk Between Neurons and Astrocytes in Response to Bilirubin: Adverse Secondary Impacts. Neurotoxicity Research, 2014, 26, 1-15.	2.7	13
124	Bilirubin mediated oxidative stress involves antioxidant response activation via Nrf2 pathway. Cellular Signalling, 2014, 26, 512-520.	3.6	106
125	Life-Long Correction of Hyperbilirubinemia with a Neonatal Liver-Specific AAV-Mediated Gene Transfer in a Lethal Mouse Model of Criglerâ€“Najjar Syndrome. Human Gene Therapy, 2014, 25, 844-855.	2.7	74
126	Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women. Journal of Endocrinological Investigation, 2014, 37, 739-744.	3.3	11

#	Article	IF	Citations
127	Neonatal hyperbilirubinemia. Italian Journal of Pediatrics, 2014, 40, A10.	2.6	1
128	Translational approaches: from fatty liver to non-alcoholic steatohepatitis. World Journal of Gastroenterology, 2014, 20, 9038-49.	3.3	43
129	Epidemiology of fatty liver: an update. World Journal of Gastroenterology, 2014, 20, 9050-4.	3.3	71
130	Cold storage of liver microorgans in ViaSpan and BG35 solutions: study of ammonia metabolism during normothermic reoxygenation. Annals of Hepatology, 2014, 13, 256-64.	1.5	2
131	Alterations in the redox state and liver damage: Hints from the EASL Basic School of Hepatology. Journal of Hepatology, 2013, 58, 365-374.	3.7	51
132	Bilirubin-Induced Neurologic Damage â€" Mechanisms and Management Approaches. New England Journal of Medicine, 2013, 369, 2021-2030.	27.0	284
133	The biological implication of cancer stem cells in hepatocellular carcinoma: a possible target for future therapy. Expert Review of Gastroenterology and Hepatology, 2013, 7, 749-757.	3.0	7
134	Podocyte Expression of Membrane Transporters Involved in Puromycin Aminonucleoside-Mediated Injury. PLoS ONE, 2013, 8, e66159.	2.5	7
135	Specific Inhibition of the Redox Activity of Ape1/Ref-1 by E3330 Blocks Tnf-Î-Induced Activation of Il-8 Production in Liver Cancer Cell Lines. PLoS ONE, 2013, 8, e70909.	2.5	37
136	The Expression of CD90/Thy-1 in Hepatocellular Carcinoma: An In Vivo and In Vitro Study. PLoS ONE, 2013, 8, e76830.	2.5	70
137	Alterations in the Cell Cycle in the Cerebellum of Hyperbilirubinemic Gunn Rat: A Possible Link with Apoptosis?. PLoS ONE, 2013, 8, e79073.	2.5	19
138	Alcohol and Nutrition as Risk Factors for Chronic Liver Disease. , 2013, , 497-506.		1
139	Kinetics of the inflammatory response induced by free fatty acid accumulation in hepatocytes. Annals of Hepatology, 2013, 13, 113-20.	1.5	5
140	Bilirubin accumulation and Cyp mRNA expression in selected brain regions of jaundiced Gunn rat pups. Pediatric Research, 2012, 71, 653-660.	2.3	45
141	Kernicterus, Bilirubin Induced Neurological Dysfunction and New Treatments for Unconjugated Hyperbilirubinemia. , 2012, , 621-628.		1
142	Rescue of bilirubinâ€induced neonatal lethality in a mouse model of Criglerâ€Najjar syndrome type I by AAV9â€mediated gene transfer. FASEB Journal, 2012, 26, 1052-1063.	0.5	71
143	Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma. BMC Gastroenterology, 2012, 12, 160.	2.0	44
144	Transport and Metabolism at Bloodâ€"Brain Interfaces and in Neural Cells: Relevance to Bilirubin-Induced Encephalopathy. Frontiers in Pharmacology, 2012, 3, 89.	3.5	29

#	Article	IF	Citations
145	Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. BMC Gastroenterology, 2012, 12, 20.	2.0	109
146	Targeted multicomponent polysomes for high efficiency, simultaneous anti-sense and gene delivery. Soft Matter, 2011, 7, 9424.	2.7	2
147	Bilirubin-induced neurological damage. Journal of Maternal-Fetal and Neonatal Medicine, 2011, 24, 154-155.	1.5	8
148	Modulation of Mrp1 (ABCc1) and Pgp (ABCb1) by Bilirubin at the Blood-CSF and Blood-Brain Barriers in the Gunn Rat. PLoS ONE, 2011, 6, e16165.	2.5	48
149	Functional Induction of the Cystine-Glutamate Exchanger System Xc- Activity in SH-SY5Y Cells by Unconjugated Bilirubin. PLoS ONE, 2011, 6, e29078.	2.5	28
150	Xâ€ray fluorescence elemental mapping and microscopy to follow hepatic disposition of a Gdâ€based magnetic resonance imaging contrast agent. Clinical and Experimental Pharmacology and Physiology, 2011, 38, 834-845.	1.9	12
151	Effect of bilirubin on cytochrome c oxidase activity of mitochondria from mouse brain and liver. BMC Research Notes, 2010, 3, 162.	1.4	18
152	A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterology, 2010, 10, 98.	2.0	188
153	A proteomic approach to the bilirubinâ€induced toxicity in neuronal cells reveals a protective function of DJâ€1 protein. Proteomics, 2010, 10, 1645-1657.	2.2	32
154	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nature Genetics, 2010, 42, 658-660.	21.4	389
155	Heterologous Ferredoxin Reductase and Flavodoxin Protect Cos-7 Cells from Oxidative Stress. PLoS ONE, 2010, 5, e13501.	2.5	12
156	Galectin-1 and Its Involvement in Hepatocellular Carcinoma Aggressiveness. Molecular Medicine, 2010, 16, 102-115.	4.4	69
157	Ungebundenes (freies) Bilirubin: eine bessere Grundlage fÃ¼r die Bewertung des Icterus neonatorum / Unbound (free) bilirubin: improving the paradigm for evaluating neonatal jaundice. Laboratoriums Medizin, 2010, 34, 15-27.	0.6	0
158	Kinetics and Specificity of Feline Leukemia Virus Subgroup C Receptor (FLVCR) Export Function and Its Dependence on Hemopexin. Journal of Biological Chemistry, 2010, 285, 28874-28882.	3.4	74
159	Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. World Journal of Hepatology, 2010, 2, 114.	2.0	42
160	Unconjugated bilirubin modulates nitric oxide production via iNOS regulation. BioScience Trends, 2010, 4, 244-8.	3.4	15
161	Subzero nonfreezing storage of rat hepatocytes using UW solution and 1,4-butanediol. II- functional testing on rewarming and gene expression of urea cycle enzymes. Annals of Hepatology, 2009, 8, 129-133.	1.5	5
162	Unbound (Free) Bilirubin: Improving the Paradigm for Evaluating Neonatal Jaundice. Clinical Chemistry, 2009, 55, 1288-1299.	3.2	124

#	Article	IF	Citations
163	SOCS3 and IRS-1 gene expression differs between genotype 1 and genotype 2 hepatitis C virus-infected HepG2 cells. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1217-25.	2.3	22
164	A transcriptome analysis identifies molecular effectors of unconjugated bilirubin in human neuroblastoma SH-SY5Y cells. BMC Genomics, 2009, 10, 543.	2.8	26
165	The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Medicine, 2009, 7, 21.	5.5	132
166	Modern strategies to identify new molecular targets for the treatment of liver diseases: The promising role of Proteomics and Redox Proteomics investigations. Proteomics - Clinical Applications, 2009, 3, 242-262.	1.6	10
167	Systematic review and meta-analysis on the adverse events of rimonabant treatment: Considerations for its potential use in hepatology. BMC Gastroenterology, 2009, 9, 75.	2.0	19
168	Differential Proteomic Analysis of Subfractioned Human Hepatocellular Carcinoma Tissues. Journal of Proteome Research, 2009, 8, 2273-2284.	3.7	14
169	Bilirubin inhibits the TNFÎ±-related induction of three endothelial adhesion molecules. Biochemical and Biophysical Research Communications, 2009, 386, 338-344.	2.1	76
170	Effective Treatment of Unconjugated Hyperbilirubinemia With Oral Bile Salts in Gunn Rats. Gastroenterology, 2009, 136, 673-682.e1.	1.3	30
171	The Many Functions of APE1/Ref-1: Not Only a DNA Repair Enzyme. Antioxidants and Redox Signaling, 2009, 11, 601-619.	5.4	424
172	The cytotoxic effect of unconjugated bilirubin in human neuroblastoma SH-SY5Y cells is modulated by the expression level of MRP1 but not MDR1. Biochemical Journal, 2009, 417, 305-312.	3.7	22
173	Editorial [Hot Topic: Bilirubin Induced Neurological Damage: From the Cell to the Newborn (Executive) Tj ETQq1 1 0.784314 rgBT /Ov	1.9	6
174	Bilirubin effect on endothelial adhesion molecules expression is mediated by the NF-kappaB signaling pathway. BioScience Trends, 2009, 3, 151-7.	3.4	30
175	Differential expression of the multidrug resistanceâ€related proteins ABCb1 and ABCc1 between bloodâ€brain interfaces. Journal of Comparative Neurology, 2008, 510, 497-507.	1.6	135
176	Liver and heart: A new link?. Journal of Hepatology, 2008, 49, 300-302.	3.7	33
177	Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends in Molecular Medicine, 2008, 14, 72-81.	6.7	381
178	Are non-invasive tests accurate enough to predict hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD)?. Gut, 2008, 57, 1351-1353.	12.1	10
179	Natural Course of Chronic HCV and HBV Infection and Role of Alcohol in the General Population: The Dionysos Study. American Journal of Gastroenterology, 2008, 103, 2248-2253.	0.4	75
180	Clinical update on non-alcoholic fatty liver disease and steatohepatitis. Annals of Hepatology, 2008, 7, 157-60.	1.5	4

#	Article	IF	Citations
181	Cytotoxicity Is Predicted by Unbound and Not Total Bilirubin Concentration. Pediatric Research, 2007, 62, 576-580.	2.3	60
182	Drug-induced acute cholestatic liver damage in a patient with mutation of UGT1A1. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 403-408.	1.7	19
183	Subcellular Localization of APE1/Ref-1 in Human Hepatocellular Carcinoma: Possible Prognostic Significance. Molecular Medicine, 2007, 13, 89-96.	4.4	93
184	Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virusâ€“related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology, 2007, 46, 1009-1015.	7.3	150
185	Incidence and natural course of fatty liver in the general population: The Dionysos study. Hepatology, 2007, 46, 1387-1391.	7.3	192
186	Bilirubin-induced cell toxicity involves PTEN activation through an APE1/Ref-1-dependent pathway. Journal of Molecular Medicine, 2007, 85, 1099-1112.	3.9	41
187	Multidrug resistance associated protein 1 protects against bilirubin-induced cytotoxicity. FEBS Letters, 2006, 580, 1355-1359.	2.8	29
188	Gene expression and activity of urea cycle enzymes of rat hepatocytes cold stored up to 120h in University of Wisconsin solution. Cryobiology, 2006, 52, 393-400.	0.7	6
189	Gene Expression Analysis in HBV Transgenic Mouse Liver: A Model to Study Early Events Related to Hepatocarcinogenesis. Molecular Medicine, 2006, 12, 115-123.	4.4	31
190	Blood Flow Changes in Hepatocellular Carcinoma After the Administration of Thalidomide Assessed by Reperfusion Kinetics During Microbubble Infusion. Investigative Radiology, 2006, 41, 15-21.	6.2	41
191	The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology, 2006, 6, 33.	2.0	1,817
192	Proteomic analysis of liver tissues subjected to early ischemia/reperfusion injury during human orthotopic liver transplantation. Proteomics, 2006, 6, 3455-3465.	2.2	53
193	Efficient cold transfection of pea ferredoxin-NADP(H) oxidoreductase into rat hepatocytes. Journal of Gene Medicine, 2006, 8, 306-313.	2.8	4
194	Hepatitis B virus genotypes, core promoter variants, and precore stop codon variants in patients infected chronically in North-Eastern Italy. Journal of Medical Virology, 2006, 78, 734-740.	5.0	27
195	Novel Kinetic Insights into Treatment of Unconjugated Hyperbilirubinemia: Phototherapy and Orlistat Treatment in Gunn Rats. Pediatric Research, 2006, 59, 506-512.	2.3	18
196	Abnormal apolipoprotein B pre-mRNA splicing in patients with familial hypobetalipoproteinaemia. Journal of Medical Genetics, 2006, 44, 219-224.	3.2	17
197	Factors Affecting the Binding of Bilirubin to Serum Albumins: Validation and Application of the Peroxidase Method. Pediatric Research, 2006, 60, 724-728.	2.3	67
198	Molecular Determinants in the Transport of a Bile Acid-Derived Diagnostic Agent in Tumoral and Nontumoral Cell Lines of Human Liver. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 809-817.	2.5	51

#	Article	IF	Citations
199	Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology, 2005, 42, 44-52.	7.3	1,118
200	Vagaries of impaired transporter function in PFIC 2 and 3. Hepatology, 2005, 42, 977-978.	7.3	2
201	Magnetic Resonance Contrast Agents: From the Bench to the Patient. Current Pharmaceutical Design, 2005, 11, 4079-4098.	1.9	38
202	Intestinal flora and bilirubin. Journal of Hepatology, 2005, 42, 170-172.	3.7	28
203	Bilirubin and the risk of common non-hepatic diseases. Trends in Molecular Medicine, 2005, 11, 277-283.	6.7	60
204	Response to Zucker: bilirubin and non-hepatic disease: a less jaundiced view. Trends in Molecular Medicine, 2005, 11, 314-315.	6.7	0
205	Overoxidation of peroxiredoxins as an immediate and sensitive marker of oxidative stress in HepG2 cells and its application to the redox effects induced by ischemia/reperfusion in human liver. Free Radical Research, 2005, 39, 255-268.	3.3	58
206	Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1). Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2470-2475.	7.1	148
207	Anti-Transglutaminase Antibodies and Age. Clinical Chemistry, 2004, 50, 1856-1860.	3.2	10
208	Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology, 2004, 126, 102-110.	1.3	389
209	Molecular basis of bilirubin-induced neurotoxicity. Trends in Molecular Medicine, 2004, 10, 65-70.	6.7	171
210	The epidemiology of fatty liver. European Journal of Gastroenterology and Hepatology, 2004, 16, 1087-1093.	1.6	116
211	The human multidrug-resistance-associated protein MRP1 mediates ATP-dependent transport of unconjugated bilirubin. Biochemical Journal, 2004, 383, 335-341.	3.7	65
212	Upregulation in the expression of multidrug resistance protein Mrp1 mRNA and protein by increased bilirubin production in rat. Biochemical and Biophysical Research Communications, 2003, 311, 891-896.	2.1	20
213	Effects of maturation on RNA transcription and protein expression of four MRP genes in human placenta and in BeWo cells. Biochemical and Biophysical Research Communications, 2003, 303, 259-265.	2.1	87
214	Evaluation of liver parenchymal blood flow with contrast-enhanced US. Academic Radiology, 2003, 10, 869-876.	2.5	10
215	Editorial: The North-to-South Gradient of Hepatitis C Virus Infection. Scandinavian Journal of Gastroenterology, 2003, 38, 805-806.	1.5	6
216	Correspondence. Pediatric Research, 2003, 54, 926-926.	2.3	22

#	Article	IF	Citations
217	Reassessment of the Unbound Concentrations of Unconjugated Bilirubin in Relation to Neurotoxicity In Vitro. Pediatric Research, 2003, 54, 98-104.	2.3	85
218	Alcohol and Nutrition as Risk Factors for Chronic Liver Disease. , 2003, , 73-85.		0
219	In vitro and in vivo hepatic transport of the magnetic resonance imaging contrast agent B22956/1: role of MRP proteins. Biochemical and Biophysical Research Communications, 2002, 293, 100-105.	2.1	37
220	Gene Expression of ABC Proteins in Hepatocellular Carcinoma, Perineoplastic Tissue, and Liver Diseases. Molecular Medicine, 2002, 8, 318-325.	4.4	49
221	Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy. Journal of Medical Virology, 2002, 68, 352-356.	5.0	60
222	Low solubility of unconjugated bilirubin in dimethylsulfoxide–water systems: implications for pKa determinations. BMC Biochemistry, 2002, 3, 17.	4.4	25
223	Mechanisms of bilirubin neurotoxicity. Hepatology, 2002, 35, 1277-1280.	7.3	36
224	Ammonium detoxifying activity is maintained after 72 hours of cold preservation of rat hepatocytes in University of Wisconsin (UW) solution. Cryo-Letters, 2002, 23, 245-54.	0.3	6
225	New concepts in bilirubin neurotoxicity and the need for studies at clinically relevant bilirubin concentrations. Journal of Hepatology, 2001, 34, 467-470.	3.7	21
226	Variation in UGT1A1 activity in Gilbert's syndrome. Journal of Hepatology, 2001, 34, 636-637.	3.7	1
227	DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study. Journal of Hepatology, 2001, 34, 587-592.	3.7	96
228	The spectrum of liver disease in the general population: lesson from the Dionysos study. Journal of Hepatology, 2001, 35, 531-537.	3.7	213
229	ABC Protein Transport of MRI Contrast Agents in Canalicular Rat Liver Plasma Vesicles and Yeast Vacuoles. Biochemical and Biophysical Research Communications, 2001, 282, 60-66.	2.1	63
230	Preparation of an Antibody Recognizing both Human and Rodent MRP1. Biochemical and Biophysical Research Communications, 2001, 288, 1064-1068.	2.1	21
231	Mechanisms for the transport of unconjugated bilirubin in human trophoblastic BeWo cells. FEBS Letters, 2001, 495, 94-99.	2.8	58
232	Genetic Determinants of Ethanol-Induced Liver Damage. Molecular Medicine, 2001, 7, 255-262.	4.4	75
233	High prevalence of celiac disease in Italian general population. Digestive Diseases and Sciences, 2001, 46, 1500-1505.	2.3	138
234	Hepatic uptake of organic anions affects the plasma bilirubin level in subjects with Gilbert's syndrome mutations in UGT1A1. Hepatology, 2001, 33, 627-632.	7.3	36

#	Article	IF	Citations
235	Tauroursodeoxycholic acid protects hepatocytes from ethanol-fed rats against tumor necrosis factorâ€“induced cell death by replenishing mitochondrial glutathione. Hepatology, 2001, 34, 964-971.	7.3	75
236	An improved method for isolation of unconjugated bilirubin from rat and dog bile. Translational Research, 2001, 137, 370-373.	2.3	8
237	Pitfalls in preparation of 3H-unconjugated bilirubin by biosynthetic labeling from precursor 3H-5-aminolevulinic acid in the dog. Translational Research, 2001, 138, 313-321.	2.3	11
238	Affinity of Human Serum Albumin for Bilirubin Varies with Albumin Concentration and Buffer Composition. Journal of Biological Chemistry, 2001, 276, 29953-29960.	3.4	101
239	Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy. Annals of Internal Medicine, 2000, 132, 112.	3.9	1,051
240	The products ofYCF1 andYLL015w (BPT1) cooperate for the ATP-dependent vacuolar transport of unconjugated bilirubin inSaccharomyces cerevisiae. Yeast, 2000, 16, 561-571.	1.7	68
241	Epidemiology of hepatitis C virus infection in Italy: the slowly unraveling mystery. Microbes and Infection, 2000, 2, 1757-1763.	1.9	34
242	Risk factors for alcoholic liver disease. Addiction Biology, 2000, 5, 261-268.	2.6	12
243	Rapid Method for Detection of Extra (TA) in the Promoter of the Bilirubin-UDP-Glucuronosyl Transferase 1 Gene Associated with Gilbert Syndrome. Clinical Chemistry, 2000, 46, 129-131.	3.2	26
244	Detection of MRP1 mRNA in Human Tumors and Tumor Cell Lines by in Situ RT-PCR. Biochemical and Biophysical Research Communications, 2000, 275, 466-471.	2.1	14
245	Cohort effect of HCV infection in liver cirrhosis assessed by a 25 year study. Journal of Clinical Virology, 2000, 17, 51-56.	3.1	14
246	Ethanol-induced apoptosis in vitro. Clinical Biochemistry, 1999, 32, 547-555.	1.9	49
247	Familial clustering of Helicobacter pylori infection: population based study Â Commentary: Helicobacter pylori---the story so far. BMJ: British Medical Journal, 1999, 319, 537-541.	2.3	92
248	Uptake of [3H]bilirubin in freshly isolated rat hepatocytes: role of free bilirubin concentration. FEBS Letters, 1999, 463, 143-145.	2.8	21
249	Molecular Mechanisms for the Hepatic Uptake of Magnetic Resonance Imaging Contrast Agents. Biochemical and Biophysical Research Communications, 1999, 257, 746-752.	2.1	95
250	Inhibition of Glutamate Uptake by Unconjugated Bilirubin in Cultured Cortical Rat Astrocytes: Role of Concentration and pH. Biochemical and Biophysical Research Communications, 1999, 265, 67-72.	2.1	92
251	Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells. Gastroenterology, 1998, 115, 157-166.	1.3	120
252	Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients. Journal of Hepatology, 1998, 29, 650-659.	3.7	45

#	Article	IF	Citations
253	ATP-dependent transport of unconjugated bilirubin by rat liver canalicular plasma membrane vesicles. Biochemical Journal, 1998, 331, 99-103.	3.7	17
254	Binding of tritiated bilirubin to albumin and plasma membrane vesicles: a reply. Biochemical Journal, 1997, 321, 261-261.	3.7	0
255	Noninvasive in vivo quantitative assessment of fat content in human liver. Journal of Hepatology, 1997, 27, 108-113.	3.7	283
256	Chronic Administration of Ursodeoxycholic and Tauroursodeoxycholic Acid Changes Microsomal Membrane Lipid Content and Fatty Acid Composition in Rats. Biochemical and Biophysical Research Communications, 1996, 220, 479-483.	2.1	19
257	Albumin binding of unconjugated [3H]bilirubin and its uptake by rat liver basolateral plasma membrane vesicles. Biochemical Journal, 1996, 316, 999-1004.	3.7	29
258	Hepatitis C virus and nonâ€Hodgkin's lymphomas. British Journal of Haematology, 1996, 94, 544-550.	2.5	171
259	Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. Journal of Magnetic Resonance Imaging, 1995, 5, 281-285.	3.4	340
260	Interferon therapy in chronic hepatitis C virus: Evidence of different outcome with respect to different viral strains. Journal of Medical Virology, 1995, 45, 445-450.	5.0	43
261	Effect of tauroursodeoxycholic and ursodeoxycholic acid on ethanol-induced cell injuries in the human Hep G2 cell line. Gastroenterology, 1995, 109, 555-563.	1.3	78
262	Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease. Journal of Medical Virology, 1994, 43, 291-296.	5.0	156
263	Prevalence of chronic liver disease in the general population of northern Italy: The dionysos study. Hepatology, 1994, 20, 1442-1449.	7.3	504
264	Competition of bile acids on the sulfobromophthalein uptake in basolateral rat liver plasma membrane vesicles. Biochemical Pharmacology, 1994, 48, 1301-1304.	4.4	5
265	Strategies in the study of hepatocellular carcinoma worldwide. Journal of Surgical Oncology, 1993, 53, 37-39.	1.7	2
266	Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rat. Digestive Diseases and Sciences, 1993, 38, 1291-1296.	2.3	26
267	Difference in hepatic uptake of tetra- and Di-bromosulfophthalein in rat. Biochemical Pharmacology, 1993, 46, 925-931.	4.4	6
268	Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. Journal of Hepatology, 1993, 19, 459-464.	3.7	57
269	Fatty Infiltration of the Liver. Investigative Radiology, 1993, 28, 297-302.	6.2	222
270	Transport of sulfobromophthalein and taurocholate in the HepG2 cell line in relation to the expression of membrane carrier proteins. Biochemical and Biophysical Research Communications, 1992, 183, 1203-1208.	2.1	30

#	Article	IF	Citations
271	Determinants in the hepatic uptake of organic anions. Journal of Hepatology, 1992, 14, 385-390.	3.7	20
272	Epomediol ameliorates pruritus in patients with intrahepatic cholestasis of pregnancy. Journal of Hepatology, 1992, 16, 241-242.	3.7	23
273	Effect of ethinylestradiol and epomediol on bile flow and biliary lipid composition in rat. Biochemical Pharmacology, 1992, 43, 1289-1293.	4.4	17
274	Severity of liver disease with different hepatitis C viral clones. Lancet, The, 1991, 338, 509.	13.7	199
275	Biochemical and molecular aspects of the hepatic uptake of organic anions. BBA - Biomembranes, 1990, 1031, 261-275.	8.0	65
276	Abnormal hepatic uptake of low doses of sulfobromophthalein in Gilbert's syndrome: The role of reduced affinity of the plasma membrane carrier of organic anions. Hepatology, 1990, 12, 213-217.	7.3	20
277	Detection of hepatitis B virus transcripts in patients with chronic liver disease. Journal of Hepatology, 1990, 10, 180-185.	3.7	1
278	Prevalence of hepatocellular carcinoma and relation to cirrhosis: Comparison of two different cities of the worldâ€"Trieste, Italy, and Chiba, Japan. Hepatology, 1989, 10, 998-1002.	7.3	80
279	[6] Isolation of bilitranslocase, the anion transporter from liver plasma membrane for bilirubin and other organic anions. Methods in Enzymology, 1989, 174, 50-57.	1.0	22
280	Reversal of ethinylestradiol-induced cholestasis by epomediol in rat. Biochemical Pharmacology, 1989, 38, 3559-3563.	4.4	24
281	Role and nature of plasma membrane carrier proteins in the hepatic transport of organic anions. Journal of Gastroenterology and Hepatology (Australia), 1989, 4, 195-205.	2.8	4
282	Estrogens keep alive the hepatocyte memory. Hepatology, 1988, 8, 693-695.	7.3	1
283	Sex steroid modulation of the hepatic uptake of organic anions in rat. Journal of Hepatology, 1988, 6, 343-349.	3.7	18
284	The Hepatic Uptake of Organic Anions: An Overview. , 1987, , 31-40.		0
285	Serum free fatty acids and bilirubin concentration during fasting in patients with Gilbertâ€™s syndrome and normal controls. Research in Clinic and Laboratory, 1987, 17, 61-6.	0.3	1
286	Cellular localization of sulfobromophthalein transport activity in rat liver. Biochimica Et Biophysica Acta - Biomembranes, 1986, 856, 1-10.	2.6	46
287	Mechanisms of hepatic uptake of organic anions. Clinical Science, 1986, 71, 1-8.	4.3	22
288	Membrane potential and hepatic uptake: Another rule of the game. Hepatology, 1986, 6, 1049-1050.	7.3	0

#	Article	IF	Citations
289	Clinical, biochemical and histological features of primary haemochromatosis: a report of 67 cases. Liver, 1986, 6, 310-315.	0.1	24
290	The implication of bilitranslocase function in the impaired rifamycin SV metabolism in Gilbert's syndrome. Clinical Science, 1985, 68, 675-680.	4.3	20
291	Serum type III procollagen peptide in alcoholic liver disease and idiopathic hemochromatosis: Its relationship to hepatic fibrosis, activity of the disease and iron overload. Hepatology, 1985, 5, 475-479.	7.3	49
292	Comparison of nicotinic acid- and caloric restriction-induced hyperbilirubinaemia in the diagnosis of gilbert's syndrome. Journal of Hepatology, 1985, 1, 537-543.	3.7	19
293	Sex differences of nicotinate-induced hyperbilirubinemia in Gilbert's syndrome. Journal of Hepatology, 1985, 1, 417-429.	3.7	24
294	Measurement of the association of cholephylic organic anions with different binding proteins. Biochemical Pharmacology, 1985, 34, 2439-2444.	4.4	22
295	Estimation of the hepatic blood â€œflowâ€•by galactose plasma clearance in patients with liver disease. Liver, 1985, 5, 129-133.	0.1	9
296	Effect of Phototherapy on the Physiologic Cholestasis of the Neonate. Journal of Pediatric Gastroenterology and Nutrition, 1984, 3, 230-233.	1.8	0
297	Serum Marker of Type III Procollagen in Patients with Idiopathic Hemochromatosis and Its Relationship to Hepatic Fibrosis. American Journal of Clinical Pathology, 1983, 80, 499-502.	0.7	22
298	Further studies on bilitranslocase, a plasma membrane protein involved in hepatic organic anion uptake. Biochimica Et Biophysica Acta - Biomembranes, 1982, 685, 117-122.	2.6	54
299	Reconstitution in vitro of sulfobromophthalein transport by bilitranslocase. Biochimica Et Biophysica Acta - Biomembranes, 1982, 685, 123-128.	2.6	62
300	Isolation of a sulfobromophthalein-binding protein from hepatocyte plasma membrane. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1978, 532, 105-112.	1.7	78
301	Modeling, identification and parameter estimation of bilirubin kinetics in normal, hemolytic and Gilbert's states. Journal of Biomedical Informatics, 1975, 8, 522-537.	0.7	25
302	Bilirubin and inflammation in neurodegenerative and other neurological diseases. Neuroimmunology and Neuroinflammation, 0, 2020, .	1.4	13
303	On the operational definition of fatty liver. Qeios, 0, , .	0.0	0
304	Novel Function for Bilirubin as a Metabolic Signaling Molecule: Implications for Kidney Diseases. Kidney360, 0, , 10.34067/KID.0000062022.	2.1	2